Literature DB >> 29608492

Impact of Cardiac Resynchronization Therapy on Left Ventricular Unloading in Patients with Implanted Left Ventricular Assist Devices.

David M Tehrani1, Sirtaz Adatya1, Jonathan Grinstein2, Daniel Rodgers1, Nitasha Sarswat1, Gene H Kim1, Jayant Raikhelkar1, Gabriel Sayer1, Nir Uriel1.   

Abstract

Cardiac resynchronization therapy (CRT) and left ventricular assist devices (LVADs) are common heart failure therapies; however, little is known regarding the concomitant use of these devices. We aim to evaluate unloading differences in LVAD patients with and without active biventricular pacing. Left ventricular assist device patients with and without CRT prospectively underwent ramp hemodynamic/echocardiographic testing. Patients with >95% biventricular pacing comprised the active CRT pacing group; all others (no device, implantable cardioverter defibrillator only, CRT without biventricular pacing) were categorized into the non-CRT pacing group. Invasive hemodynamics and echocardiographic characteristics (left ventricular end-diastolic/systolic diameter and valvular regurgitation) were measured at baseline and at incremental speed changes. Unloading slopes were calculated using linear regression modeling for individual hemodynamics and echocardiographic characteristics across speeds. Among 62 LVAD patients (age 59.6 ± 11.4 years, 60% male), 25 had active CRT pacing. There was no significant difference in echocardiographic or hemodynamic characteristics at baseline or final set speeds between CRT groups. Similarly, no significant differences were noted in the unloading characteristics. In LVAD patients, active biventricular pacing is unlikely to improve echocardiographic or hemodynamic characteristics.

Entities:  

Mesh:

Year:  2019        PMID: 29608492      PMCID: PMC6221999          DOI: 10.1097/MAT.0000000000000787

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  24 in total

1.  Long-term use of a left ventricular assist device for end-stage heart failure.

Authors:  E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

2.  Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy.

Authors:  Scott D Solomon; Elyse Foster; Mikhail Bourgoun; Amil Shah; Esperanza Viloria; Mary W Brown; W Jackson Hall; Marc A Pfeffer; Arthur J Moss
Journal:  Circulation       Date:  2010-08-23       Impact factor: 29.690

3.  Survival benefit of implantable cardioverter-defibrillators in left ventricular assist device-supported heart failure patients.

Authors:  Marwan M Refaat; Toshikazu Tanaka; Robert L Kormos; Dennis McNamara; Jeffrey Teuteberg; Steve Winowich; Barry London; Marc A Simon
Journal:  J Card Fail       Date:  2011-12-22       Impact factor: 5.712

4.  Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator.

Authors:  Daniel J Cantillon; Khaldoun G Tarakji; Dharam J Kumbhani; Nicholas G Smedira; Randall C Starling; Bruce L Wilkoff
Journal:  Heart Rhythm       Date:  2010-01-04       Impact factor: 6.343

5.  Impact of cardiac resynchronization therapy on clinical outcomes in patients with continuous-flow left ventricular assist devices.

Authors:  Rakesh Gopinathannair; Emma J Birks; Jaimin R Trivedi; Kelly C McCants; Brad S Sutton; Allen G Deam; Mark S Slaughter; Rashmi U Hottigoudar
Journal:  J Card Fail       Date:  2014-12-17       Impact factor: 5.712

6.  Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients.

Authors:  Joseph G Rogers; Keith D Aaronson; Andrew J Boyle; Stuart D Russell; Carmelo A Milano; Francis D Pagani; Brooks S Edwards; Soon Park; Ranjit John; John V Conte; David J Farrar; Mark S Slaughter
Journal:  J Am Coll Cardiol       Date:  2010-04-27       Impact factor: 24.094

7.  Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes.

Authors:  Robert L Kormos; Jeffrey J Teuteberg; Francis D Pagani; Stuart D Russell; Ranjit John; Leslie W Miller; Todd Massey; Carmelo A Milano; Nader Moazami; Kartik S Sundareswaran; David J Farrar
Journal:  J Thorac Cardiovasc Surg       Date:  2010-02-04       Impact factor: 5.209

8.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

9.  Treatment of cardiogenic shock with left ventricular assist device combined with cardiac resynchronization therapy: a case report.

Authors:  Håvard Keilegavlen; Jan Erik Nordrehaug; Svein Faerestrand; Rune Fanebust; Reidar Pettersen; Rune Haaverstad; Vegard Tuseth
Journal:  J Cardiothorac Surg       Date:  2010-07-02       Impact factor: 1.637

10.  The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices.

Authors:  Alan D Enriquez; Brandon Calenda; Marc A Miller; Anelechi C Anyanwu; Sean P Pinney
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-07-19
View more
  2 in total

Review 1.  Current Review of Implantable Cardioverter Defibrillator Use in Patients With Left Ventricular Assist Device.

Authors:  Jacinthe Boulet; Emmanuelle Massie; Blandine Mondésert; Yoan Lamarche; Michel Carrier; Anique Ducharme
Journal:  Curr Heart Fail Rep       Date:  2019-12

2.  Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices.

Authors:  Brett Tomashitis; Catalin F Baicu; Ross A Butschek; Gregory R Jackson; Jeffrey Winterfield; Ryan J Tedford; Michael R Zile; Michael R Gold; Brian A Houston
Journal:  J Am Heart Assoc       Date:  2021-03-05       Impact factor: 5.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.